Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 48.77
INCY's Cash-to-Debt is ranked lower than
51% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. INCY: 48.77 )
Ranked among companies with meaningful Cash-to-Debt only.
INCY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.35  Med: 1.51 Max: No Debt
Current: 48.77
0.35
No Debt
Equity-to-Asset 0.72
INCY's Equity-to-Asset is ranked higher than
55% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. INCY: 0.72 )
Ranked among companies with meaningful Equity-to-Asset only.
INCY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.83  Med: 0.21 Max: 0.92
Current: 0.72
-1.83
0.92
Debt-to-Equity 0.01
INCY's Debt-to-Equity is ranked higher than
99% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. INCY: 0.01 )
Ranked among companies with meaningful Debt-to-Equity only.
INCY' s Debt-to-Equity Range Over the Past 10 Years
Min: -17.62  Med: 0 Max: 97.27
Current: 0.01
-17.62
97.27
Debt-to-EBITDA -0.64
INCY's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. INCY: -0.64 )
Ranked among companies with meaningful Debt-to-EBITDA only.
INCY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -14.97  Med: 1.55 Max: 173.16
Current: -0.64
-14.97
173.16
Piotroski F-Score: 7
Altman Z-Score: 12.74
Beneish M-Score: -2.07
WACC vs ROIC
13.87%
-21.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % -5.45
INCY's Operating Margin % is ranked higher than
68% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. INCY: -5.45 )
Ranked among companies with meaningful Operating Margin % only.
INCY' s Operating Margin % Range Over the Past 10 Years
Min: -4064.53  Med: -2.74 Max: 14.69
Current: -5.45
-4064.53
14.69
Net Margin % -5.92
INCY's Net Margin % is ranked higher than
69% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. INCY: -5.92 )
Ranked among companies with meaningful Net Margin % only.
INCY' s Net Margin % Range Over the Past 10 Years
Min: -4565.45  Med: -19.57 Max: 9.43
Current: -5.92
-4565.45
9.43
ROE % -6.58
INCY's ROE % is ranked higher than
73% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. INCY: -6.58 )
Ranked among companies with meaningful ROE % only.
INCY' s ROE % Range Over the Past 10 Years
Min: -30.55  Med: 14.59 Max: 35.29
Current: -6.58
-30.55
35.29
ROA % -4.64
INCY's ROA % is ranked higher than
75% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. INCY: -4.64 )
Ranked among companies with meaningful ROA % only.
INCY' s ROA % Range Over the Past 10 Years
Min: -70.43  Med: -14.67 Max: 7.88
Current: -4.64
-70.43
7.88
ROC (Joel Greenblatt) % -34.67
INCY's ROC (Joel Greenblatt) % is ranked higher than
72% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. INCY: -34.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INCY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4727.38  Med: -73.03 Max: 115.22
Current: -34.67
-4727.38
115.22
3-Year Revenue Growth Rate 35.10
INCY's 3-Year Revenue Growth Rate is ranked higher than
84% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. INCY: 35.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INCY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -61.4  Med: 25.5 Max: 523.4
Current: 35.1
-61.4
523.4
3-Year EPS without NRI Growth Rate -74.10
INCY's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. INCY: -74.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INCY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -30.7 Max: 45.1
Current: -74.1
0
45.1
GuruFocus has detected 2 Warning Signs with Incyte Corp INCY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INCY's 30-Y Financials

Financials (Next Earnings Date: 2018-10-31)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

INCY Guru Trades in Q3 2017

Manning & Napier Advisors, Inc 1,071,325 sh (New)
Leon Cooperman 100,000 sh (New)
Paul Tudor Jones 17,943 sh (New)
Stanley Druckenmiller 75,400 sh (New)
Caxton Associates 2,200 sh (New)
Steven Cohen 164,600 sh (+723.00%)
Joel Greenblatt 121,896 sh (+73.02%)
Vanguard Health Care Fund 9,466,973 sh (+2.18%)
Ron Baron 10,630 sh (+0.31%)
Eaton Vance Worldwide Health Sciences Fund 176,462 sh (unchged)
Frank Sands 7,569,964 sh (-5.18%)
Mario Gabelli 2,400 sh (-7.69%)
Ken Fisher 14,022 sh (-9.72%)
Pioneer Investments 75,148 sh (-83.62%)
» More
Q4 2017

INCY Guru Trades in Q4 2017

Jim Simons 756,400 sh (New)
Pioneer Investments 471,468 sh (+527.39%)
Frank Sands 8,191,287 sh (+8.21%)
Vanguard Health Care Fund 9,466,973 sh (unchged)
Ron Baron Sold Out
Leon Cooperman Sold Out
Caxton Associates Sold Out
Stanley Druckenmiller Sold Out
Joel Greenblatt Sold Out
Ken Fisher 13,671 sh (-2.50%)
Mario Gabelli 2,300 sh (-4.17%)
Steven Cohen 70,000 sh (-57.47%)
Paul Tudor Jones 7,006 sh (-60.95%)
Eaton Vance Worldwide Health Sciences Fund 124,411 sh (-29.50%)
» More
Q1 2018

INCY Guru Trades in Q1 2018

Paul Tudor Jones 32,198 sh (+359.58%)
Mario Gabelli 2,800 sh (+21.74%)
Jim Simons 920,600 sh (+21.71%)
Frank Sands 9,768,698 sh (+19.26%)
Pioneer Investments 504,957 sh (+7.10%)
Vanguard Health Care Fund 9,466,973 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 124,411 sh (unchged)
Steven Cohen 55,000 sh (-21.43%)
Ken Fisher 6,104 sh (-55.35%)
» More
Q2 2018

INCY Guru Trades in Q2 2018

Steven Cohen 1,299,673 sh (+2263.04%)
Paul Tudor Jones 49,087 sh (+52.45%)
Ken Fisher 7,123 sh (+16.69%)
Vanguard Health Care Fund 10,657,473 sh (+12.58%)
Pioneer Investments 531,663 sh (+5.29%)
Eaton Vance Worldwide Health Sciences Fund 135,194 sh (+8.67%)
Mario Gabelli Sold Out
Jim Simons 614,500 sh (-33.25%)
Frank Sands 4,773,209 sh (-51.14%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-06-30 Add 12.58%0.18%$60.85 - $83.98 $ 66.06-3%10,657,473
Ken Fisher 2018-06-30 Add 16.69%$60.85 - $83.98 $ 66.06-3%7,123
Mario Gabelli 2018-06-30 Sold Out $60.85 - $83.98 $ 66.06-3%0
Ken Fisher 2018-03-31 Reduce -55.35%$83.06 - $100.98 $ 66.06-27%6,104
Mario Gabelli 2018-03-31 Add 21.74%$83.06 - $100.98 $ 66.06-27%2,800
Ken Fisher 2017-12-31 Reduce -2.50%$93.56 - $116.6 $ 66.06-37%13,671
Mario Gabelli 2017-12-31 Reduce -4.17%$93.56 - $116.6 $ 66.06-37%2,300
Joel Greenblatt 2017-12-31 Sold Out 0.21%$93.56 - $116.6 $ 66.06-37%0
Ron Baron 2017-12-31 Sold Out 0.01%$93.56 - $116.6 $ 66.06-37%0
Leon Cooperman 2017-12-31 Sold Out 0.45%$93.56 - $116.6 $ 66.06-37%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541714    SIC: 8731
Compare:OCSE:GEN, OCSE:NZYM B, NAS:NKTR, XBRU:UCB, NAS:BMRN, NAS:BIVV, HKSE:02269, NAS:JUNO, NAS:ALNY, NAS:BGNE, NAS:JAZZ, XMCE:GRF.P, NAS:BLUE, HKSE:01177, NAS:SGEN, NAS:AVXS, NAS:NBIX, NAS:ALKS, NAS:SAGE, NAS:EXEL » details
Traded in other countries:INCY.Austria, ICY.Germany,
Headquarter Location:USA
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which is licensed by Eli Lilly, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including IDO inhibitor epacadostat and next-generation JAK inhibitor itacitinib.

Top Ranked Articles about Incyte Corp

Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)
FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY
Incyte, Merck Fall on Failed Late-Stage Study The skin cancer treatment did not meet primary objectives
Pharmaceutical company Incyte Corp. (NASDAQ:INCY) announced on Friday that its skin cancer drug, in combination with Merck & Co. Inc. (NYSE:MRK)'s Keytruda, failed to meet its primary objective in a late-stage study, sending shares of both companies lower. Read more...
Analysts Take Action on Health Care Stocks Incyte, Illumina and Medtronic upgraded, Johnson & Johnson and Edwards Lifesciences downgraded
Analysts took action on health care stocks this week. Read more...
Here's What the Latest Incyte Deal Means for the Company Here's a look at the structure of the Incyte-Macrogenics transaction and why it's important for the companies on either side
Incyte Corp. (NASDAQ:INCY) just announced a fresh deal with small-cap biotechnology company MacroGenics Inc. (NASDAQ:MGNX), and both companies are picking up some strength on the back of the news. MacroGenics traded at a close to 20% premium to its preannouncement market capitalization Wednesday morning. Incyte was up a couple of percentage points, having spiked in the early session but subsequently settled down. Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 26.39
INCY's Forward PE Ratio is ranked lower than
77% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. INCY: 26.39 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 8.10
INCY's PB Ratio is ranked lower than
73% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. INCY: 8.10 )
Ranked among companies with meaningful PB Ratio only.
INCY' s PB Ratio Range Over the Past 10 Years
Min: 7.67  Med: 45.3 Max: 391.93
Current: 8.1
7.67
391.93
PS Ratio 8.13
INCY's PS Ratio is ranked higher than
60% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INCY: 8.13 )
Ranked among companies with meaningful PS Ratio only.
INCY' s PS Ratio Range Over the Past 10 Years
Min: 7.17  Med: 20.38 Max: 239.71
Current: 8.13
7.17
239.71
Price-to-Operating-Cash-Flow 869.21
INCY's Price-to-Operating-Cash-Flow is ranked lower than
98% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. INCY: 869.21 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
INCY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.19  Med: 190.05 Max: 974.08
Current: 869.21
7.19
974.08
EV-to-EBIT -143.13
INCY's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. INCY: -143.13 )
Ranked among companies with meaningful EV-to-EBIT only.
INCY' s EV-to-EBIT Range Over the Past 10 Years
Min: -8534.9  Med: -11.3 Max: 1569.2
Current: -143.13
-8534.9
1569.2
EV-to-EBITDA -337.02
INCY's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. INCY: -337.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
INCY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -8534.9  Med: -13.4 Max: 1569.2
Current: -337.02
-8534.9
1569.2
EV-to-Revenue 7.44
INCY's EV-to-Revenue is ranked higher than
65% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. INCY: 7.44 )
Ranked among companies with meaningful EV-to-Revenue only.
INCY' s EV-to-Revenue Range Over the Past 10 Years
Min: 7.1  Med: 20.55 Max: 273.2
Current: 7.44
7.1
273.2
Current Ratio 4.34
INCY's Current Ratio is ranked lower than
51% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. INCY: 4.34 )
Ranked among companies with meaningful Current Ratio only.
INCY' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.5 Max: 21.14
Current: 4.34
1.51
21.14
Quick Ratio 4.32
INCY's Quick Ratio is ranked higher than
52% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. INCY: 4.32 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s Quick Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.49 Max: 21.14
Current: 4.32
1.51
21.14
Days Inventory 19.37
INCY's Days Inventory is ranked higher than
87% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. INCY: 19.37 )
Ranked among companies with meaningful Days Inventory only.
INCY' s Days Inventory Range Over the Past 10 Years
Min: 14.49  Med: 35.36 Max: 323.15
Current: 19.37
14.49
323.15
Days Sales Outstanding 66.76
INCY's Days Sales Outstanding is ranked lower than
52% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. INCY: 66.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.25  Med: 52.27 Max: 6447.52
Current: 66.76
12.25
6447.52
Days Payable 315.70
INCY's Days Payable is ranked higher than
86% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. INCY: 315.70 )
Ranked among companies with meaningful Days Payable only.
INCY' s Days Payable Range Over the Past 10 Years
Min: 310.77  Med: 1723.24 Max: 32457.1
Current: 315.7
310.77
32457.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.30
INCY's 3-Year Average Share Buyback Ratio is ranked higher than
69% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. INCY: -7.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INCY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.8  Med: -8.4 Max: -0.6
Current: -7.3
-17.8
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 26.32
INCY's Price-to-Net-Cash is ranked lower than
84% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. INCY: 26.32 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INCY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.43  Med: 8.58 Max: 450
Current: 26.32
1.43
450
Price-to-Net-Current-Asset-Value 15.02
INCY's Price-to-Net-Current-Asset-Value is ranked lower than
77% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. INCY: 15.02 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INCY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.23  Med: 9.95 Max: 3615
Current: 15.02
1.23
3615
Price-to-Tangible-Book 10.39
INCY's Price-to-Tangible-Book is ranked lower than
75% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. INCY: 10.39 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INCY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.91  Med: 6.47 Max: 340.56
Current: 10.39
0.91
340.56
Price-to-Intrinsic-Value-Projected-FCF 9.79
INCY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
83% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. INCY: 9.79 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
INCY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 9.91  Med: 17.14 Max: 138.66
Current: 9.79
9.91
138.66
Price-to-Median-PS-Value 0.39
INCY's Price-to-Median-PS-Value is ranked higher than
84% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. INCY: 0.39 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INCY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.82 Max: 11.08
Current: 0.39
0.11
11.08
Earnings Yield (Greenblatt) % -0.70
INCY's Earnings Yield (Greenblatt) % is ranked higher than
74% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. INCY: -0.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INCY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -37.7  Med: -0.8 Max: 1.3
Current: -0.7
-37.7
1.3

More Statistics

Revenue (TTM) (Mil) $1,729.49
EPS (TTM) $ -0.50
Beta1.83
Volatility33.07%
52-Week Range $60.23 - 117.95
Shares Outstanding (Mil)212.58

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 1,762 2,045 2,334 2,677
EBIT (Mil $) 169 427 727
EBITDA (Mil $) 249 531 877 1,217
EPS ($) 0.60 1.84 2.99 3.57
EPS without NRI ($) 0.60 1.84 2.99 3.57
EPS Growth Rate
(Future 3Y To 5Y Estimate)
74.84%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}